Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your genes raise lung cancer risk? new study investigates

NCT ID NCT06181812

Knowledge-focused Sponsor: Oscar Gerardo Arrieta Rodríguez Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find how often inherited gene changes occur in Mexican patients with a type of lung cancer called adenocarcinoma. Researchers will collect blood samples from 332 participants to look for these gene changes and see if they affect survival or treatment options. The study does not offer a treatment but helps understand genetic risks in this population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 332 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with lung adenocarcinoma treated in the Thoracic Oncology Unit of the National Institute of Cancer.

Ages

16 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Both sexes * ≥ 16 years old, according the institutional protocols for new patients admittances. * histologically confirmed lung adenocarcinoma (LUAD) * Signed written informed consent form * A life expectancy greater than 8 weeks. * Histologically confirmed LUAD and one of the following conditions: i) LCFH, defined as having one first-degree relative (FDR) or two or more second-degree relatives with LC, irrespective of the age at diagnosis. ii) Age at diagnosis ≤50 years, or ≤60 with a pack-years index. iii) Presence of ≥1 AGAs (EGFR, ALK, ROS1, KRAS, BRAF, MET exon 14 skipping, or RET). Exclusion Criteria: * A sample of peripheral blood that is not accessible. * Insufficient clinical pathological information in the electronic clinical record. Elimination Criteria: * Withdrawal * Insufficient DNA quality and quantity for genomic sequencing analyses. * Lost of follow up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología

    RECRUITING

    Mexico City, Mexico City, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.